Standard BioTools (NASDAQ:LAB) Director Casdin Partners Master Fund, L Acquires 450,000 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 450,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was acquired at an average price of $1.30 per share, with a total value of $585,000.00. Following the completion of the transaction, the director directly owned 64,050,000 shares in the company, valued at $83,265,000. This trade represents a 0.71% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Wednesday, November 19th, Casdin Partners Master Fund, L bought 350,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.28 per share, for a total transaction of $448,000.00.
• On Tuesday, November 18th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.23 per share, with a total value of $338,250.00.
• On Monday, November 17th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.22 per share, with a total value of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.24 per share, for a total transaction of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.20 per share, with a total value of $540,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L bought 375,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.19 per share, with a total value of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L purchased 300,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.20 per share, with a total value of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L acquired 275,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.17 per share, for a total transaction of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.12 per share, for a total transaction of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L bought 100,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.29 per share, with a total value of $129,000.00.

Standard BioTools Stock Performance

Shares of LAB stock opened at $1.30 on Friday. Standard BioTools Inc. has a 52 week low of $0.92 and a 52 week high of $2.25. The company has a market capitalization of $498.01 million, a price-to-earnings ratio of -4.05 and a beta of 1.25. The company has a 50-day simple moving average of $1.28 and a 200 day simple moving average of $1.23.

Hedge Funds Weigh In On Standard BioTools

A number of hedge funds have recently added to or reduced their stakes in the stock. Jump Financial LLC bought a new stake in shares of Standard BioTools during the 1st quarter valued at $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after purchasing an additional 14,541 shares in the last quarter. CWM LLC raised its stake in Standard BioTools by 101.8% in the first quarter. CWM LLC now owns 29,705 shares of the company’s stock valued at $32,000 after purchasing an additional 14,984 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Standard BioTools by 2,989.0% during the third quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock worth $33,000 after purchasing an additional 24,211 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in Standard BioTools by 50.3% during the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company’s stock worth $36,000 after buying an additional 9,986 shares in the last quarter. Institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Cowen downgraded Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. TD Cowen decreased their price objective on Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a report on Wednesday, November 5th. Finally, Wall Street Zen downgraded Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $1.35.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.